Sumita Ray

CIK: 0001579629

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)4 (50.0%)

Position reduction

Option Exercises (M)1 (12.5%)

Derivative conversions

Awards (A)3 (37.5%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

CUE

Cue Biopharma, Inc.

Officer

BMEA

Biomea Fusion, Inc.

Director

Discretionary Trading P&L

Holdings

Transaction History (8 total)

CUE
Cue Biopharma, Inc.
Oct 12, 2026
Sale(S)
Direct
1.8K shares at avg. $28.05$52K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Exercise(M)
Direct
18.2K shares-
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
2.4K shares at avg. $29.37$70K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
6.4K shares at avg. $30.35$196K
CUE
Cue Biopharma, Inc.
Aug 13, 2026
Sale(S)
Direct
4 shares at avg. $31.13$124.52
CUE
Cue Biopharma, Inc.
Jul 9, 2026
Award(A)
Direct
54.6K shares-
BMEA
Biomea Fusion, Inc.
Jun 10, 2026
Award(A)
Stock Option (Right to Buy)
Direct
196.3K shares-
BMEA
Biomea Fusion, Inc.
Jun 11, 2025
Award(A)
Stock Option (Right to Buy)
Direct
92K shares-

		Type	Shares	Price		Ownership
Oct 12, 2026	CUE Cue Biopharma, Inc.	Sale(S)	1,844	$28.05	$51,724	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Exercise(M)	18,196	-	$0	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	2,383	$29.37	$69,989	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	6,442	$30.35	$195,515	Direct
Aug 13, 2026	CUE Cue Biopharma, Inc.	Sale(S)	4	$31.13	$125	Direct
Jul 9, 2026	CUE Cue Biopharma, Inc.	Award(A)	54,589	-	$0	Direct
Jun 10, 2026	BMEA Biomea Fusion, Inc.	Award(A) Stock Option (Right to Buy)	196,299	-	-	Direct
Jun 11, 2025	BMEA Biomea Fusion, Inc.	Award(A) Stock Option (Right to Buy)	91,970	-	-	Direct

1-8 of 8 transactions

About Ray Sumita

Ray Sumita (SEC CIK 0001579629) files insider reports with the SEC as Chief Legal Compliance Officer of Cue Biopharma, Inc. (CUE) and Director of Biomea Fusion, Inc. (BMEA).

Signal8 holds 6 ownership filings by Ray Sumita (1 Form 3, 5 Form 4), filed between Jun 13, 2025 and Oct 14, 2026. Those filings report 8 transactions, from Jun 11, 2025 to Oct 12, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Ray Sumita's filings is in SOMERVILLE, MA.

Recent filings by Ray Sumita

Oct 12, 2026: Open-market sale of CUE shares (Form 4, code S).
Aug 13, 2026: Option exercise of CUE shares (Form 4, code M).
Aug 13, 2026: Open-market sales of CUE shares (3 lines, Form 4, code S).
Jul 9, 2026: Grant or award of CUE shares (Form 4, code A).
Jun 10, 2026: Grant or award of BMEA derivative securities (Form 4, code A).

Other insiders filing for Cue Biopharma, Inc. (CUE)

Meluzio Michael Vincent, VP, Prin. Accounting Officer
Lin Shao-Lee, Chief Executive Officer
Sarraf Pasha, Director
Garzone Pamela, Director
Ahlers James M, Chief Financial Officer
Borie Dominique Christian, Chief Medical Officer

How to read Form 4 transaction codes